Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanksMar 19 08:11 ET
Allogene Therapeutics Analyst Ratings
BenzingaMar 19 06:53 ET
Allogene Therapeutics Analyst Ratings
BenzingaMar 15 12:17 ET
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TipRanksMar 15 00:40 ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
TipRanksMar 12 12:50 ET
Allogene Therapeutics Analyst Ratings
BenzingaFeb 27 13:17 ET
Allogene Therapeutics Analyst Ratings
BenzingaJan 19 06:37 ET
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Allogene Therapeutics (ALLO)
TipRanksJan 5 07:00 ET
Allogene Therapeutics Analyst Ratings
BenzingaJan 5 06:25 ET
Allogene Therapeutics Analyst Ratings
BenzingaDec 8, 2023 07:52 ET
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $12
BenzingaNov 15, 2023 07:38 ET
Allogene Therapeutics Analyst Ratings
BenzingaNov 15, 2023 07:34 ET
Allogene Therapeutics Analyst Ratings
BenzingaSep 25, 2023 09:33 ET
JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating
MT NewswiresSep 25, 2023 08:13 ET
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target
BenzingaAug 7, 2023 06:21 ET
Allogene Therapeutics Analyst Ratings
BenzingaAug 7, 2023 06:21 ET
Allogene Therapeutics Analyst Ratings
BenzingaAug 3, 2023 07:38 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (ALLO), Zur Rose Group AG (Six Swiss: CH:DOCM) and Fresenius SE & Co. KGaA (GB:0OO9)
TipRanksAug 3, 2023 05:07 ET
Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18
BenzingaJul 12, 2023 11:31 ET
Allogene Therapeutics Analyst Ratings
BenzingaJul 12, 2023 11:29 ET
No Data
No Data